Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 StudyJustin M. Watts, Pankit Vachhani, Alessandro M. Vannucchi et al.|Blood|2023Cited by 5
Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 StudyJustin M. Watts, Pankit Vachhani, Emma Searle et al.|Blood|2024Cited by 5
Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.Justin M. Watts, Pankit Vachhani, Anthony M. Hunter et al.|Journal of Clinical Oncology|2023Cited by 1
P1055: BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDYJustin M. Watts, Pankit Vachhani, Anthony M. Hunter et al.|HemaSphere|2023Cited by 1
Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.Justin M. Watts, Pankit Vachhani, Alessandro M. Vannucchi et al.|Journal of Clinical Oncology|2024Cited by 1